Comparative Pharmacology
Head-to-head clinical analysis: METHIMAZOLE versus POTASSIUM IODIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHIMAZOLE versus POTASSIUM IODIDE.
METHIMAZOLE vs POTASSIUM IODIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones (T3 and T4). Also inhibits peripheral conversion of T4 to T3.
Potassium iodide suppresses thyroid hormone synthesis and release via the Wolff-Chaikoff effect, inhibiting iodide organification and reducing vascularity of the thyroid gland.
Oral, initial dose 15-40 mg daily in 3 divided doses; maintenance dose 5-15 mg daily
Oral: 300 mg (0.3 mL of saturated solution) three times daily for thyroid protection in radiation exposure; for hyperthyroidism preoperative: 60-250 mg (0.06-0.25 mL) three times daily.
None Documented
None Documented
4-6 hours in euthyroid patients; prolonged to 10-15 hours in hyperthyroid patients. Clinical context: steady-state achieved in 2-3 days, but therapeutic effect on thyroid hormone synthesis requires 3-8 weeks due to depletion of stored hormones.
Clinical Note
moderateMethimazole + Prednisolone
"The serum concentration of Prednisolone can be decreased when it is combined with Methimazole."
Clinical Note
moderateMethimazole + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Methimazole resulting in a loss in efficacy."
Clinical Note
moderateMethimazole + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole."
Clinical Note
moderateTerminal half-life in euthyroid individuals is approximately 13 days (range 10–15 days). In hyperthyroidism, half-life may be shortened to 5–6 days due to increased thyroid clearance; in hypothyroidism, half-life may be prolonged up to 40 days.
Primarily renal (65-70% as unchanged drug and metabolites), with minor biliary/fecal elimination (<10%).
Renal: >90% of absorbed iodide is excreted in urine; fecal elimination is negligible (<2%).
Category D/X
Category C
Antithyroid Agent
Antithyroid Agent
Methimazole + Clozapine
"The risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine."